

Date of preparation: 3 February 2026

Issuer's abbreviated name: SYNEKTIK SA

Current report: 12/2026 ESPI

Subject: First notification of intent to carry out a division of Synektik SA

Legal basis: Article 539 § 1 in conjunction with Article 402¹ § 1 of the Polish Commercial Companies Code

Body of the report:

Time of publication: 11:11 a.m.

The Management Board of Synektik Spółka Akcyjna with its registered Office in Warsaw ("Divided Company"), acting pursuant to Article 539 § 1–2 of the Polish Commercial Companies Code, hereby gives notice to the shareholders for the first time of its intention to carry out a division of the Divided Company and to transfer part of its assets to Syn2bio Spółka Akcyjna with its registered office in Warsaw (address: ul. Józefa Piusa Dziekońskiego 3, 00-728 Warsaw), entered in the register of entrepreneurs of the National Court Register kept by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, under KRS number 0001186962, holding tax identification number (NIP) 521-412-82-14 and statistical number (REGON) 542419239, with a share capital of PLN 100,000.00, fully paid up ("Acquiring Company").

The division of the Divided Company will be carried out in accordance with Article 529 § 1(4) of the Polish Commercial Companies Code by transferring to the Acquiring Company a part of the assets of the Divided Company in the form of an organized part of the Divided Company's enterprise, comprising an organizationally and financially separate set of tangible and intangible assets intended for the performance of specific economic tasks related to Cardiotracer and CBNC (in accordance with the definitions contained in the Division Plan), constituting an organized part of the enterprise within the meaning of the provisions of tax law.

The division shall be carried out under the terms and conditions specified in the division plan, which will be made available free of charge together with its appendices, as well as the documents referred to in Article 540 § 1-2 of the Polish Commercial Companies Code, to the public on July 23, 2025, on the website of the Divided Company (<https://synektik.com.pl/centrum-inwestora/plan-podzialu/>), and on the website of the Acquiring Company (<https://syn2bio.pl/>) („Division Plan”). The consolidated text of the Division Plan, as well as the opinion of the statutory auditor on the examination of the Division Plan, were made available as appendices to the Divided Company’s current report No. 44/2025 dated 3 September 2025 on the website of the Acquiring Company. The indicated documentation will remain available on those websites until the conclusion of the general meetings of the Divided Company and the Acquiring Company adopting the resolution on the division. The Division Plan and the above-mentioned documents will also be available throughout the entire period at the registered offices of the Divided Company and the Acquiring Company at ul. Józefa Piusa Dziekońskiego 3 in Warsaw.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board